Differentiating T-Cell Engager Use Vs Standard Therapy in Multiple Myeloma
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
IDMC Recommends Continuation of ELI-002 7P Trial in PDAC
The independent data monitoring committee confirmed the favorable safety profile of ELI-002 7P for the treatment of PDAC in the phase 1/2 AMPLIFY-7P trial.
Highlighting Bispecific Use Across Multiple Myeloma Indications
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
New ASPHO President Hopes to Increase Awareness Around Pediatric Oncology
While Maria C. Velez, MD’s, term as president of ASPHO is only 1 year, she is already confident in ASPHO’s strategic plans.
FDA Accepts sBLA, Grants Priority Review to Liso-Cel in Pretreated MZL
Results from the marginal zone lymphoma cohort of the TRANSCEND FL trial showed liso-cel elicited an ORR of 95.5% and a CR rate of 62.1%.
TIL Therapy Provides Excitement Despite Room to Grow in Melanoma Care
At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.
Data Show MRD in Nearly Half of Ovarian Cancer Population in Remission
Further studying the biology of minimal residual disease may uncover ovarian cancer vulnerabilities and inform more effective therapies.
Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma
More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.
Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC
Following the approval of dato-DXd in untreated EGFR-mutant NSCLC, Jacob Sands, MD, discussed next steps for improving outcomes for this disease.
FDA Issues CRL to Odronextamab in Pretreated Follicular Lymphoma
The complete response letter for the agent is due to observations from an FDA general site inspection at Catalent Indiana, LLC.
INKmune Exhibits Favorable Safety in Metastatic CRPC
Developers plan to initiate a phase 2b trial in patients with less severe prostate cancer variants to better assess INKmune’s antitumor effects.
Looking Towards the Future of Peritoneal Surface Malignancy Care
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management
Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.
Outlining Next Steps for Tarlatamab in Early-Line ES-SCLC and Beyond
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
Enhanced Representation Is Key in New Peritoneal Surface Malignancy Guidelines
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
Aumolertinib Has Long-Term Survival Benefit in NSCLC With Brain Metastases
Nonrandomized phase 2 data support further assessment of aumolertinib among patients with NSCLC and brain metastases in a randomized clinical trial.
Tarlatamab Provides Clinicians New Immunologic Option in SCLC
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
National ICE-T Conference Aims to Make CAR T Safer and More Available
Leading experts gathered in Orlando, FL, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.
Dato-DXd Shows Favorable Benefit in EGFR-Mutant NSCLC
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
Pembrolizumab/Axitinib Improves Survival vs Sunitinib in Advanced RCC
The biomarker analysis in KEYNOTE-426 showed that pembrolizumab plus axitinib therapy is associated with positive outcomes with angiogenesis in RCC.
CAR T-Cell Therapies Show Superior Efficacy, Safety in Multiple Myeloma
Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.
Tarlatamab and DLL3 May Open New Opportunities in SCLC Management
The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.
VT3989 Receives Orphan Drug Designation for the Treatment of Mesothelioma
An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.
Closing the Gap Between Academic and Community Practices in Multiple Myeloma
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Talazoparib Combo Significantly Improves Overall Survival in Metastatic CRPC
Findings from the phase 3 TALAPRO-2 trial showed that the safety profile of talazoparib was consistent with its known profile in metastatic CRPC.
Outlining Historical Standard Therapies for EGFR-Mutant NSCLC
Osimertinib/chemotherapy and amivantamab/lazertinib have exhibited an efficacy advantage vs osimertinib in patients with EGFR-mutant NSCLC.
Translating Rare Kidney Cancer Research into Clinical Trials
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Episode 9: Advancing Beyond First-Line Options in Urothelial Carcinoma Treatment
Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.
Determining Proper Sequencing for Cellular Therapies in Multiple Myeloma
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Early Recurrence Post-Pembrolizumab Inspires Zanzalitinib Trial in ccRCC
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
![“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F9b290688648a249e516474c175a3c06309426d15-2950x1568.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.")
